Workflow
再鼎医药:2025年第一季度总收入1.06亿美元,同比增长22%
09688ZAI LAB(09688) 快讯·2025-05-08 10:53

Core Insights - The company reported total revenue of 106millionforQ12025,representingayearoveryearincreaseof22106 million for Q1 2025, representing a year-over-year increase of 22% [1] - Product revenue netted 106 million, showing a year-over-year growth of 21% [1] - Operating loss was 56.3million,adecreaseof2056.3 million, a decrease of 20% compared to the previous year, while adjusted operating loss was 37.1 million, down 25% year-over-year [1] - As of March 31, 2025, the company had cash reserves of 857million[1]Thecompanyprojectsfullyearrevenueguidancefor2025tobebetween857 million [1] - The company projects full-year revenue guidance for 2025 to be between 560 million and $590 million [1]